RT Journal Article SR Electronic T1 Mitochondrial induced T cell apoptosis and aberrant myeloid metabolic programs define distinct immune cell subsets during acute and recovered SARS-CoV-2 infection JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.09.10.20186064 DO 10.1101/2020.09.10.20186064 A1 Elizabeth A. Thompson A1 Katherine Cascino A1 Alvaro A. Ordonez A1 Weiqiang Zhou A1 Ajay Vaghasia A1 Anne Hamacher-Brady A1 Nathan R. Brady A1 Im-Hong Sun A1 Rulin Wang A1 Avi Z. Rosenberg A1 Michael Delannoy A1 Richard Rothman A1 Katherine Fenstermacher A1 Lauren Sauer A1 Kathyrn Shaw-Saliba A1 Evan M. Bloch A1 Andrew D. Redd A1 Aaron AR Tobian A1 Maureen Horton A1 Kellie Smith A1 Andrew Pekosz A1 Franco R. D’Alessio A1 Srinivasan Yegnasubramanian A1 Hongkai Ji A1 Andrea L. Cox A1 Jonathan D. Powell YR 2020 UL http://medrxiv.org/content/early/2020/09/11/2020.09.10.20186064.abstract AB By interrogating metabolic programs in the peripheral blood mononuclear cells (PBMC) of acutely infected COVID-19 patients, we identified novel and distinct immune cell subsets Our studies identified a non-clonal population of T cells expressing high H3K27me3 and voltage-dependent anion channel (VDAC) with mitochondrial dysfunction and increased susceptibility to cell death. Characterized by dysmorphic mitochondria and increased cytoplasmic cytochrome c, apoptosis of these cells was inhibited by preventing VDAC aggregation or blocking caspase activation. Further, we observed a marked increase in Hexokinase II+polymorphonuclear-myeloid derived suppressor cells (PMN-MDSC). While PMN-MDSC were also found in the PBMC of patients with other viral infections, the Hexokinase II+ PMN-MDSC were found exclusively in the acute COVID-19 patients with moderate or severe disease. Finally, we identified a population of monocytic MDSC (M-MDSC) expressing high carnitine palmitoyltransferase I (CPT1a) and VDAC, which were present in the PBMC of the acute COVID-19 patients, but not recovered COVID-19 patients and whose presence correlated with severity of disease. Overall, these unique populations of immune cells provide insight into the pathogenesis of SARS-CoV-2 infection and provide a means to predict and track disease severity as well as an opportunity to design and evaluate novel therapeutic regimens.One Sentence Summary Metabolic programs define unique immune cells among COVID-19 patients with severe diease.Competing Interest StatementJ.D.P. is a scientific founder, a paid consultant and has equity in Dracen Pharmaceuticals.Funding StatementFunding for this work was provided by a Johns Hopkins University Provost Research Grant, The Bill and Melinda Gates Foundation (134582), NIH Centers of Excellence in Influenza Research and Surveillance (HHSN272201400007C) and NIH (P41EB028239 to JDP). The study was supported in part by a cooperative agreement between Johns Hopkins University (JHU) and the Division of Intramural Research, NIAID, NIH, as well as extramural support from the US Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA; grant number IDSEP160031-01-00) and National Institute of Allergy and Infectious Diseases (R01AI120938, R01AI120938S1, R01AI128779, and U19A1088791). Contract HHSN272201400007C awarded to A.A.R.T the Johns Hopkins Center for Influenza Research and Surveillance (JHCEIRS) at the Johns Hopkins University. Confocal microscopy images acquired from Zeis LSM880 was supported by National Institute of General Medical Sciences (NIGMS) of the National Institutes of Health (S10OD023548 to JHUSOM Microscope Facility). The Core for Clinical Research Data Acquisition is supported in part by the Johns Hopkins Institute for Clinical and Translational Research (UL1TR001079).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Patients diagnosed with COVID-19 by positive SARS-CoV-2 RNA testing through the Johns Hopkins Healthcare System were enrolled in a protocol designed to generate a biospecimen repository linked to clinical data for investigation (Johns Hopkins Medicine (JHM) IRB 00245545) and another for analysis of research questions specific to immunology (JHM IRB 00255162). Following JHM IRB approval, PBMC samples were obtained under informed consent from: HCV infected patients (JHM IRB NA_0004638), hospitalized patients infected with influenza in 2019 (JHM IRB 00091667) and SARS-CoV-2 convalescent plasma donors (JHM IRB 00248402, JHM IRB 00250798)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available upon request.